Patents by Inventor Bastian Theisinger

Bastian Theisinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12005033
    Abstract: The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: June 11, 2024
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Patent number: 11844836
    Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: December 19, 2023
    Assignee: DERMALIQ THERAPEUTICS, INC.
    Inventors: Bernhard Gunther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Patent number: 11324757
    Abstract: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: May 10, 2022
    Assignee: NOVALIQ GMBH
    Inventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
  • Patent number: 11160865
    Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: November 2, 2021
    Assignee: NOVALIQ GMBH
    Inventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
  • Patent number: 10813999
    Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: October 27, 2020
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Gunther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Publication number: 20200188318
    Abstract: The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.
    Type: Application
    Filed: September 20, 2019
    Publication date: June 18, 2020
    Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Patent number: 10576154
    Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: March 3, 2020
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Dieter Scherer, Anthony Pettigrew, Bastian Theisinger, Sonja Theisinger
  • Patent number: 10555953
    Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: February 11, 2020
    Assignee: NOVALIQ GMBH
    Inventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
  • Patent number: 10525062
    Abstract: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: January 7, 2020
    Assignee: NOVALIQ GMBH
    Inventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
  • Patent number: 10449164
    Abstract: The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: October 22, 2019
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Patent number: 10369117
    Abstract: The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: August 6, 2019
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Patent number: 10130707
    Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: November 20, 2018
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Gunther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Patent number: 10058615
    Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: August 28, 2018
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Dieter Scherer, Anthony Pettigrew, Bastian Theisinger, Sonja Theisinger
  • Patent number: 10045996
    Abstract: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: August 14, 2018
    Assignee: NOVALIQ GMBH
    Inventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
  • Patent number: 9968678
    Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: May 15, 2018
    Assignee: NOVALIQ GMBH
    Inventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
  • Publication number: 20180071229
    Abstract: The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.
    Type: Application
    Filed: September 21, 2017
    Publication date: March 15, 2018
    Applicant: NOVALIQ GMBH
    Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Publication number: 20180021434
    Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.
    Type: Application
    Filed: September 29, 2017
    Publication date: January 25, 2018
    Applicant: NOVALIQ GMBH
    Inventors: Bernhard Gunther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Patent number: 9872927
    Abstract: The invention relates to a water-based biocompatible non-cytotoxic preparation for the selective staining of internal limiting membrane (ILM) and/or epiretinal membranes (ERM) in the human or animal eye, and to a kit containing said water-based preparation according to the invention.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: January 23, 2018
    Assignee: FLUORON GMBH
    Inventors: Christian Lingenfelder, Bastian Theisinger, Wilfried Hiebl, Nadine Hagedorn
  • Patent number: 9757459
    Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: September 12, 2017
    Assignee: NOVALIQ GMBH
    Inventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
  • Patent number: RE49758
    Abstract: The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: December 19, 2023
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer, Clive Wilson, Anthony Pettigrew, Annette Hüttig